Products
Search Result
Home >

Products >

glp 2 diabetes peptides online manufacturer Manufacturer

The search yielded  (4)  results

GLP-2 (1-34) (human) Diabetes Peptides CAS 99120-49-7 Catalog Number KS032009

GLP-2 (1-34) (human),CAS#: 99120-49-7, Catalog Number: KS032009 Glucagon-like peptide-2 (GLP-2) promotes nutrient absorption via expansion of the mucosal epithelium by stimulation of crypt cell proliferation and inhibition of apoptosis in the small intestine. It also reduces epithelial permeability, and decreases meal-stimulated gastric acid secretion and gastrointestinal motility. GLP-2 promotes the expansion of the intestinal epithelium through stimulation of the GLP-2

GLP-2 (1-33) (human) Diabetes Peptides CAS 223460-79-5 Catalog Number KS032008

GLP-2 (1-33) (human),CAS#: 223460-79-5, Catalog Number: KS032008 This is a fragment of human intestinal growth factor glucagon-like peptide 2, GLP2, containing amino acids 146 to 178. It is an intestinotrophic growth hormone that promotes many aspects of intestinal function, including enhancement of mucosal growth and promotion of nutrient absorption. GLP-2 is a hormone that can rapidly improve intestinal epithelial barrier function. Technical Data for GLP-2 (human) M. Wt

Amylin (rat) Diabetes Peptides CAS 124447-81-0 Catalog Number KS032012

Amylin (rat),CAS#: 124447-81-0, Catalog Number: KS032012 Rat/mouse Amylin differs from the human version in 6 amino acids: H18R, F23L, A25P, I26V, S28P and S29P (first letter is the amino acid of the human sequence). Unlike the human IAPP (Amylin), rat Amylin does not form amyloid fibers. Technical Data for Amylin (rat) M. Wt 3920.43 Formula C167H272N52O53S2 Sequence (Modifications: Tyr-37 = C-terminal amide, Disulfide bridge between 2 - 7) Storage Store at -20C CAS Number

FDA Approved Peptide APIs Sermaglutide CAS 910463-68-2 Molecular Weight 4113.64

Sermaglutide CAS 910463-68-2 Molecular Weight 4113.64 On September 20, 2019, the FDA officially approved the marketing application for Sommarutide, which is used in combination with diet and exercise to improve blood sugar control in patients with type 2 diabetes. Sommarutide is a human GLP-1 analogue with high albumin affinity and a long half-life. It can be administered once a week to stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner.

1